BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma

Journal of Investigative Dermatology

Volumn 136, Issue 2, 2016, Pages 481-486

  Groesser, Leopold ^a   Peterhof, Eva ^a   Evert, Matthias ^a   Landthaler, Michael ^a   Berneburg, Mark ^a   Hafner, Christian ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Dermatohistological Laboratory   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RAS PROTEIN; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEVUS FLAMMEUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYOGENIC GRANULOMA; SCHOOL CHILD; SOMATIC MUTATION; YOUNG ADULT; COHORT ANALYSIS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUTATION; NEEDLE BIOPSY; ONCOGENE RAS; PATHOLOGY; RETROSPECTIVE STUDY; SKIN DISEASE;

ADOLESCENT; ADULT; AGED; BIOPSY, NEEDLE; CHILD; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GRANULOMA, PYOGENIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN DISEASES;

EID: 84973442689     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/JID.2015.376     Document Type: Article

References (24)

1. Arbiser, J.L., Moses, M.A., Fernandez, C.A., et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 94 (1997), 861–866.
2. Behjati, S., Tarpey, P.S., Sheldon, H., et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46 (2014), 376–379.
3. Bottos, A., Martini, M., Di Nicolantonio, F., et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci USA 109 (2012), E353–E359.
4. Davies, H., Bignell, G.R., Cox, C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
5. Fecteau, R.E., Lutterbaugh, J., Markowitz, S.D., et al. GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PloS One, 9, 2014, e87966.
6. Garzon, M.C., Enjolras, O., Frieden, I.J., Vascular tumors and vascular malformations: evidence for an association. J Am Acad Dermatol 42 (2000), 275–279.
7. Garzon, M.C., Huang, J.T., Enjolras, O., et al. Vascular malformations: part I. J Am Acad Dermatol 56 (2007), 353–370.
8. Georgieva, I.A., Mauerer, A., Groesser, L., et al. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis. Am J Dermatopathol 36 (2014), 635–642.
9. Hassel, J.C., Groesser, L., Herschberger, E., et al. RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma. J Invest Dermatol 135 (2015), 636–639.
10. Hoeger, P.H., An update on infantile haemangiomas. Br J Dermatol, 169, 2013, 11.
11. Lim, Y.H., Douglas, S.R., Ko, C.J., et al. Somatic activating RAS mutations cause vascular tumors including pyogenic granuloma. J Invest Dermatol 135 (2015), 1698–1700.
12. Lurkin, I., Stoehr, R., Hurst, C.D., et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PloS One, 5, 2010, e8802.
13. Meadows, K.N., Bryant, P., Vincent, P.A., et al. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23 (2004), 192–200.
14. Niault, T.S., Baccarini, M., Targets of Raf in tumorigenesis. Carcinogenesis 31 (2010), 1165–1174.
15. Pagliai, K.A., Cohen, B.A., Pyogenic granuloma in children. Pediatr Dermatol 21 (2004), 10–13.
16. Patrice, S.J., Wiss, K., Mulliken, J.B., Pyogenic granuloma (lobular capillary hemangioma): a clinicopathologic study of 178 cases. Pediatr Dermatol 8 (1991), 267–276.
17. Ponti, G., Venesio, T., Losi, L., et al. BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees. J Invest Dermatol 127 (2007), 1387–1391.
18. Sammut, S.J., Tomson, N., Corrie, P., Pyogenic granuloma as a cutaneous adverse effect of vemurafenib. N Engl J Med 371 (2014), 1265–1267.
19. Shen, A.S., Peterhof, E., Kind, P., et al. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Human pathology 46 (2015), 272–276.
20. Shields, C.L., Kligman, B.E., Suriano, M., et al. Phacomatosis pigmentovascularis of cesioflammea type in 7 patients: combination of ocular pigmentation (melanocytosis or melanosis) and nevus flammeus with risk for melanoma. Arch Ophthalmol 129 (2011), 746–750.
21. Shirley, M.D., Tang, H., Gallione, C.J., et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 368 (2013), 1971–1979.
22. Su, F., Viros, A., Milagre, C., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366 (2012), 207–215.
23. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 363 (2010), 2191–2199.
24. Wellbrock, C., Karasarides, M., Marais, R., The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5 (2004), 875–885.